BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/420/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 13:53:43 2024-06-14 EDT | ||
| 5.94 EUR | +4.95% |
|
| Current month | +87.97% | ||
| 1 month | +327.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 5.94 | +4.95% |
| 24-06-13 | 5.66 | +3.10% |
| 24-06-12 | 5.49 | -6.63% |
| 24-06-11 | 5.88 | -2.16% |
| 24-06-10 | 6.01 | -2.12% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 01:53 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM3RM7 |
| ISIN | DE000VM3RM73 |
| Date issued | 2023-10-09 |
| Strike | 420 $ |
| Maturity | 2024-06-21 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 1.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.3 € |
|---|---|
| Lowest since issue | 0.71 € |
| Spread | 0.21 € |
| Spread % | 3.59% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant
